Zydus Lifesciences arm gets marketing nod for Nulibry from UK MHRA for MoCD Type A

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-04-22T14:08:22+05:30 | Updated On 22 April 2024 2:08 PM IST

Zydus Lifesciences gets USFDA nod for Glatiramer Acetate Injection for relapsing forms of Multiple Sclerosis

Ahmedabad: Zydus Lifesciences Ltd. has announced that its wholly-owned subsidiary Sentynl Therapeutics, Inc., has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for NULIBRY (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain (GB) with Molybdenum Cofactor Deficiency (MoCD) Type A.

This is an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants. It is known to impact fewer than 150 patients globally with a median survival age of four years.

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A.

"Following this decision by the UK MHRA, NULIBRY is the first and only approved therapy in GB for MoCD Type A," the Company stated.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “We are happy that with the UK MHRA approval of NULIBRY which will enable access to this critical drug and treat an ultra-rare disorder. Healthcare providers in Great Britain can now bridge the unmet needs of patients with this innovative treatment.”

Matt Heck, President & Chief Executive Officer of Sentynl said, “This approval advances our mission to make a positive impact in the lives of patients suffering from rare diseases, especially one as devastating as MoCD Type A.”

NULIBRY’s MHRA approval was supported by data from three clinical trials that demonstrated the safety and efficacy of NULIBRY for the treatment of patients with MoCD Type A compared to data from a natural history study. These studies showed that NULIBRYtreated patients had a 5.5 times lower risk of death than that of the untreated patients. Moreover, the survival probability at 3 years of age was 85.5% for NULIBRY-treated patients and 55.1% for untreated control patients.

In March 2022, Sentynl acquired the global rights to NULIBRY from BridgeBio Pharma, Inc. and is responsible for the ongoing development, manufacturing and commercialization of fosdenopterin globally.

sentynl Therapeuticsnulibryfosdenopterinsentynl therapeuticszydus lifescienceszydus lifesciences newsmolybdenum cofactor deficiency

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751